Scalper1 News
Specialty drugmaker Akorn (AKRX) said Friday that it’s buying privately held VersaPharm for $440 million, sending shares up nearly 5% after a brief trading halt in the stock market today. Akorn said the buyout, which it expects to close in Q3, will add $90 million to $100 million in annual sales and 10 to 12 cents to EPS. Analysts’ current 2015 forecast calls for sales of $693 million and EPS of $1.11. VersaPharm’s 20-product pipeline is focused Scalper1 News
Scalper1 News